SUPERNUS PHARMACEUTICALS, INC. Current State and Local Tax Expense (Benefit)
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Current State and Local Tax Expense (Benefit) of -$5.06 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentStateAndLocalTaxExpenseBenefit · last filed 2026-03-02
- SUPERNUS PHARMACEUTICALS, INC. current state and local tax expense (benefit) for fiscal 2025 was -$5.06M, a 139.18% decline from fiscal 2024.
- SUPERNUS PHARMACEUTICALS, INC. current state and local tax expense (benefit) for fiscal 2024 was $12.93M, a 102.11% increase from fiscal 2023.
- SUPERNUS PHARMACEUTICALS, INC. current state and local tax expense (benefit) for fiscal 2023 was $6.39M, a 27.71% decline from fiscal 2022.
- SUPERNUS PHARMACEUTICALS, INC. current state and local tax expense (benefit) for fiscal 2022 was $8.85M, a 7.93% increase from fiscal 2021.
| Period end | Current State and Local Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | -$5.06M 10-K · filed 2026-03-02 |
| 2024-12-31 | $12.93M 10-K · filed 2026-03-02 |
| 2023-12-31 | $6.39M 10-K · filed 2026-03-02 |
| 2022-12-31 | $8.85M 10-K · filed 2025-02-25 |
| 2021-12-31 | $8.20M 10-K · filed 2023-03-09 |
| 2020-12-31 | $11.23M 10-K · filed 2023-03-09 |
| 2019-12-31 | $10.93M 10-K · filed 2022-04-13 |
| 2018-12-31 | $5.62M 10-K · filed 2021-03-08 |
| 2017-12-31 | $3.82M 10-K · filed 2020-02-28 |
| 2016-12-31 | $78.00K 10-K · filed 2019-03-01 |
| 2015-12-31 | $42.00K 10-K · filed 2018-03-01 |
| 2011-12-31 | -$2.15M 10-K · filed 2014-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |